Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

February 28, 2023

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 43 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Corey, and I'll be serving as your conference operator for today's session. I'd like to extend a warm welcome to all of you joining Cronos Group's 2022 fourth Quarter and Full Year Earnings Conference Call. Please note that today's call is being recorded. <<operator_script>> At this point, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, the floor is yours.

Shayne Laidlaw

executive
#2

Thank you, Corey, and thanks to everyone for being with us today as we go over Cronos’ financial and business results for the fourth quarter and the full year of 2022. With me this morning are Mike Gorenstein, our Chairman, President and CEO, and James Holm, our CFO. Cronos put out a news release this morning announcing our financial results, and it has been filed on our EDGAR and SEDAR profile. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before I hand the call over to Mike, I want to remind you that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management’s current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings available on our website, and any forward-looking statements made during this call are qualified in their entirety by those materials. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials available on our website.

Shayne Laidlaw

executive
#3

We're going to give our prepared remarks at this point, and after that we'll open things up for a question-and-answer session. So with that, I'll hand things over to Mike Gorenstein, who serves as Chairman, President and CEO of Cronos.

Mike Gorenstein

executive
#4

Thank you, Shayne, and good morning to all of you. Before we get into anything else on today's call, I'd like to look back at the transformative actions we took during 2022, which positioned our company on firmer ground as we prepared for future expansion across the worldwide cannabis sector. During 2022, we began a strategic realignment of our operations built around three principal goals. The first was centralizing our function so that strategic alignment would improve. The second was streamlining our global supply chain, cutting down on complexity while boosting our capacity for innovation. Finally, we set a cost reduction goal of lowering operating expenses by an amount between $28 million and $25 million, and we beat that target. This realignment of our company revolved around our central aim of building a portfolio of products and brands without borders spanning adult-use product formats. Over the past year, we devoted considerable effort to refining our product mix for every market where we operate. That means reinforcing our borderless product portfolio, which includes edibles, vape and infused pre-rolls, along with exciting new flower genetics launching in Canada and Israel. We also made the decision to leave the CBD beauty category in the US so we could concentrate on adult-use product formats. During the quarter, our strategic initiatives and ongoing improvement work are bringing cannabinoid products to market that lift the consumer experience and take advantage of a more agile supply chain.

Mike Gorenstein

executive
#5

We're putting together a blueprint up in Canada for what we believe will succeed elsewhere. Our emphasis is on borderless product innovation — in other words, we're building brands and product lines that our experience tells us will triumph once brought into new markets. We've accomplished all of that while substantially reducing our costs and resetting how we think so growth comes with a focus on ROI and borderless innovation. With a leaner cost structure, we can fund the projects and initiatives that help Cronos grow strategically. Looking ahead to this year, we recognize there's additional cost cutting we can carry out while still preserving our innovation and growth engines. We stay sharply focused on reducing expenses across the whole business so that Cronos is positioned for long-term growth. As part of the plan to optimize our supply chain in early '22, we announced intentions to start winding down operations at our Peace Naturals Campus, which includes shutting down cultivation and shifting certain activities over to contract manufacturers. As everyone here knows, the industry we're part of keeps evolving constantly, so staying agile matters. We keep moving toward a more flexible footprint, making sure we have what's needed to execute on opportunities in both current and future markets.

Mike Gorenstein

executive
#6

So with that in mind, we've chosen to keep certain pieces of our operations running at the Peace Naturals Campus — more specifically, we intend to carry on with distribution, warehousing for some R&D work, and producing our most proprietary and innovative items. We believe this move will give us room and stability to keep expanding. Throughout this realignment, the aim from the start has been to put Cronos in position to build a portfolio of best-in-class borderless products successfully, driven by proprietary innovation, all while keeping financial flexibility intact. By deciding to stay at the Peace Naturals Campus, we're able to make select strategic investments in our R&D and brand pipeline as we innovate and respond to shifting consumer preferences. In Canada, we're continuing to carry out our plan to build a robust portfolio of borderless products, marked by several significant product launches and the ongoing success of items already on the market. All the Canadian market share figures I'll cite next come from Hifyre. In January 2023, our award-winning gummies under the Spinach brand umbrella became the top gummy in Canada, holding 15.9% market share in the edibles category. Looking at gummies alone, Spinach holds a 20.9% market share. We're delighted that our gummies have turned into a highlight in the lives of so many adult consumers, and we want to thank them for their brand loyalty and enthusiasm for our products.

Mike Gorenstein

executive
#7

SOURZ from Spinach is a product without borders, and the flavors, combinations, and sales have given us confidence that this is a winning product able to appeal to consumers in any market. In December, we introduced the Spinach FEELZ CBC gummy in select markets, and distribution has kept growing through the first quarter of ‘23. This marks the first CBC gummy product in Canada and the first product of any kind to feature a 3:1 ratio of CBC to THC. We're extremely excited about what CBC can do and have big plans for it in ‘23. Early sales indicate strong consumer adoption, and we believe this product will be additive to our overall gummy portfolio. In November, as we previously disclosed, we launched two infused pre-rolls in Canada. The first under the Spinach brand is our Fully Charged Atomic GMO, which comes in a five pack with a 0.5 gram per pre-roll. We also launched a CBG infused pre-roll under the Spinach FEELZ brand, Tropic Diesel CBG, which comes in a three pack with a 0.5 per pre-roll. These new pre-rolls are quickly climbing the market share ranks. Led by a Fully Charged Atomic GMO infused pre-roll, our pre-roll market share grew by 40 basis points sequentially from the third quarter to 1.4% in the fourth quarter.

Mike Gorenstein

executive
#8

In pre-roll we've fallen behind the market, but after a great deal of effort in this category and with the introduction of infused pre-rolls, we think the right foundation is now in place. The steps taken in ‘22 to strengthen our near-term competitive standing in pre-rolls represent only the start of what we're doing in this category. Our view is that pre-rolls, much like edibles, will be a category in which product differentiation fuels brand separation, and among our top priorities is building next generation borderless products. We're putting in extensive work to develop a product portfolio that sets us apart from competitors on several factors, among them reducing harshness, improving consistency, and meeting consumer preferences around flavor and potency. Within the base category, we reached 4.8% market share in the fourth quarter, a gain of 40 basis points in Q3, rising to number six in market share. We intend to build on that momentum in ‘23 by continuing to push toward including American <<inaudible>> in our base and by driving innovation, leading with our winning formulations across the portfolio. Although flower in the Canadian market remains heavily weighted toward 28 grams bags, we keep defending share in the 3.5 gram segment with our GMO cookies SKU, the highest ranking 3.5 gram SKU in the country at number six in the overall dried flower category.

Mike Gorenstein

executive
#9

In the fourth quarter, we held a 5.1% share of the total dried flower category, which made Spinach the number three brand in flower. During Q4, GrowCo reported preliminary unaudited revenue of roughly $2.4 million from customers other than Cronos, and for the full year, GrowCo generated revenue of approximately $21 million from non-Cronos customers. Our 50% share of GrowCo's net income, accounted for under the equity method of accounting, came in at $3.1 million in '22. Cronos had previously extended a credit facility to GrowCo, and $73.8 million is currently outstanding on it after GrowCo repaid $3.1 million of principal as of December '22. Beyond that principal repayment, Cronos also received $2.2 million in interest payments from GrowCo in '22, bringing total cash payments to Cronos to $5.2 million. GrowCo's strong financial performance, which yields equity pickup — and interest payments to Cronos — is an important component of our overall financial picture, and I believe it is an underappreciated part of our story. We are very pleased with how quickly GrowCo reached profitability, and we are excited that they are making significant strides in continuously improving our operations. GrowCo's cultivation performance continues to be strong. It achieved 30% THC potency on a recent harvest, which speaks to our JV's complementary capabilities in cultivation and downstream processing as well as our investment in genetic breeding and tissue culture.

Mike Gorenstein

executive
#10

Now regarding Israel: Peace Natural items remain solid performers for us. During the quarter just ended, we introduced two additional flower SKUs — Miami Sky and Atomic SOURZ — driven by the flower genetics and breeding program that keeps giving us an edge over rivals in Israel. Our end-market sales and marketing approaches have connected well, and consumers now equate our products with quality and consistency, which fuels the brand's success. Moving to the US market: we halted output of Happy Dance and Peace Plus in order to simplify the brand portfolio and our operations, concentrating on adult-use product formats under Lord Jones. We're glad to head into ‘23 with a tighter brand lineup and a product mix we believe will develop and grow our brand portfolio as time goes on. Our aim is to preserve the Lord Jones brand equity established in the US and make sure that, at the right moment, we can add other cannabinoids and reengage the consumer base seeking a premium hemp-derived product. Before I hand things to James, I'd like to call attention to how our roughly 10% equity stake in Australia has performed. Keep in mind that Cronos Australia recently rebranded as Vitura Health Limited, which trades on the ASX under the ticker VIT.

Mike Gorenstein

executive
#11

Vitura keeps delivering — the first half of ’23 was a record one, with gross revenue of A$57.6 million and EBITDA of A$11.8 million. Australia's medical market is still expanding, and Vitura is in an incredibly strong position to capitalize on that opportunity. At the close of ’22, our stake in Vitura was worth roughly $22 million, an asset on our balance sheet that we feel is underappreciated. Finally — and this is certainly not least — I want to congratulate and welcome James Holm, our new CFO, who came on board in November of ’22. James brings Cronos about 20 years of experience across a range of finance and accounting positions at leading companies spanning industry. During his first four months he has made an immense impact on our business, and we're eager to have him on the team helping to steer Cronos forward. With that, I'll hand things over to James to walk you through our financials.

James Holm

executive
#12

Thank you, Mike, and good morning to all of you. It's a real pleasure to be on my first Cronos earnings call, and I'm excited about everything we're going to achieve together. Now, looking at 2022 across the consolidated business, revenue rose 23% versus a year earlier, reaching $91.9 million, with the Rest of the World segment performing strongly, led by Israel and Canada. Consolidated net revenue at constant currency climbed 28% to $95.2 million. Net revenue for our Rest of the World segment came in at $86.7 million for 2022, which marks a 34% year-over-year gain. Measured at constant currency, Rest of the World net revenue grew 40% to $91 million. The United States segment fell 48% from a year ago to $5.2 million, reflecting the change in product and promotional strategy that is part of the realignment. Next, I'll walk through our fourth quarter ‘22 results compared with the prior year period. Consolidated net revenue for the fourth quarter came to $22.9 million, down 11% from the prior year period. At constant currency, consolidated net revenue declined 4% to $24.8 million. The revenue movement came mainly from a decline in the Canadian adult-use market, caused by lower cannabis flower sales that were largely the result of an unfavorable price mix shift, a revenue decline in the US segment stemming from the strategic repositioning of that business, and the effect of a weaker Canadian dollar relative to the US Dollar during the period, partly offset by growth in cannabis flower sales within the Israeli medical market.

James Holm

executive
#13

For the fourth quarter, consolidated gross profit came in at negative $0.2 million, which is a $2.2 million decrease compared with the same period a year earlier. The main drivers of that decrease were weaker cannabis flower sales in Canada — largely the result of an unfavorable price mix shift — along with higher inventory reserves in our US segment as we move away from the beauty category, plus reduced fixed cost absorption and packaging changes in the ROW segment. Partly offsetting these were greater sales of cannabis flour in Israel, a favorable mix of cannabis extract products, which carry a higher margin profile than other product categories, and lower costs for cannabis biomass. Consolidated adjusted EBITDA for the fourth quarter was negative $21.2 million, an improvement of $6.1 million versus the prior year period. That improvement came mainly from lower expenses across general and administrative, sales and marketing, and research and development. Now turning to our reporting segments: in the Rest of the World segment, net revenue for the fourth quarter was $22 million, down 3% from the prior year period. Constant currency net revenue in the Rest of the World segment rose 5% to $24 million. The revenue change was driven mainly by a decline in cannabis flower sales in Canada, largely attributable to the mix shift from 3.5 grams offerings to 28 grams offerings, and by the impact of the weakened Canadian dollar against the US Dollar during the period.

James Holm

executive
#14

That was partly offset by gains in Canadian cannabis extract plus flower sales within Israel’s medical market. For the Rest of the World segment, fourth-quarter gross profit came to $1.3 million, which is a $1.1 million drop versus the prior year period. The main drivers of that decrease were weaker fixed cost absorption, packaging changes, and an unfavorable price mix shift in the Canadian flower market, partly offset by Canadian cannabis extract growth, higher flower sales in Israel, and reduced biomass costs. Adjusted EBITDA for the Rest of the World segment in the fourth quarter was negative $13.4 million, an improvement of $1.2 million from the prior year period. That year-over-year gain was mainly due to lower research and development and general and administrative expenses. Moving to the US segment, fourth-quarter net revenue came in at $850,000, down 73% from the prior year period. The year-over-year decline resulted from reduced promotional spending and SKU rationalization tied to the strategic realignment of our US business. US segment gross profit for the fourth quarter was negative $1.5 million, a $1 million decrease from the prior year period.

James Holm

executive
#15

The year-over-year drop came mainly from softer sales volumes and higher inventory reserves tied to discontinued products, since we moved away from beauty products and concentrated on adult-use product formats. For the fourth quarter, adjusted EBITDA in the US segment was negative $4.3 million, which is a $4 million improvement from the prior year period. That gain over last year was driven mostly by lower sales and marketing and general administrative expenses. Moving to the balance sheet, the company finished the quarter with roughly $878 million in cash in short term investments, down about $11 million from the third quarter of ‘22. Just as foreign exchange rate volatility has affected our P&L, it has also had a big effect on our balance sheet. Applying the FX rates for the period ended December 31, 2021 to the current period balance sheet would give us approximately $914 million in cash in short term investments, a difference of approximately $36 million. Last year, we took significant steps to cut spending and improve our cash burn rate. We began ‘22 with a total target to reduce cash operating expenses by $20 million to $25 million, and we were able to surpass that by $3.7 million, saving a total of $28.7 million throughout ’22.

James Holm

executive
#16

In 2022, our free cash flow rose by roughly 43% compared with the year before, and the drivers were operating expenses and savings along with a cut of about 60% in CapEx, which came down to $5 million in ’22. As we moved into 2023, we’re establishing a fresh target: trimming cash operating expenses by another $10 million to $20 million. We remain deliberate in how we pursue cost cuts, so that we don’t hold back our growth or our capacity to deliver on creating borderless products. With that said, I’ll hand things back to Mike.

Mike Gorenstein

executive
#17

Thank you, James. Before we get to questions, I'd like to establish a baseline on what falls within the Cronos umbrella and where we currently stand. As of today, we ended the year holding $878 million of cash and equivalents, with no debt at all. Given how interest rates have shifted, we anticipate earning meaningful interest income on those cash balances during 2023. Revenue from our Canadian operations came to $56 million in ‘22, and inside that segment, our Spinach brand holds the market share ranges below, as reported by Hifyre data for January of ‘23. On an overall basis, Spinach ranks as the number three cannabis brand; in edibles it holds the number one position. It is the number three brand in flower, number nine in pre-rolls, and it is rapidly gaining share and moving into the number six spot in vapes while also building momentum. We hold a leading brand in Israel that brought in total revenue of $30.5 million in 2022, we possess a 6.3% stake in PharmaCann, among the biggest private US MSOs, currently carried on our books at $49 million. We hold roughly a 10% interest in Vitura, a top publicly traded Australian medical cannabis supplier valued at about $22 million at yearend, we own 50% of the equity in Cronos’ GrowCo, which is profitable, and it paid us $5.2 million in principal and interest during ‘22.

Mike Gorenstein

executive
#18

We finished the year with roughly $86 million still outstanding on the loans we made jointly to GrowCo and its partners. GrowCo's business beyond Cronos sales keeps expanding — they told us they sold $21 million to customers other than Cronos in '22. Our intellectual property portfolio keeps growing too. It covers cannabinoid fermentation, a product formulation with a patent pending, and a genetics portfolio that expands constantly. We hold real estate and several licensed facilities with no encumbrances whatsoever. And lastly, we have a worldwide exclusive partnership with Altria. When the market closed yesterday, Cronos had a market cap of about $794 million and an enterprise value of roughly negative $84 million. In my view, no cannabis company out there today carries more unrecognized value than Cronos. With that, I'll open the line for questions.

Operator

operator
#19

Michael Freeman from Raymond James gets us started.

Michael Freeman

analyst
#20

Hello there, and good morning to Mike, James, and Shayne. I really appreciate your taking our questions. First off, I want to ask — we're quite interested in the partnership you have with Ginkgo Bioworks and in how rares are being commercialized. I'm curious: after quite a few quarters of selling rare through a — distributed by way of your products — I was wondering whether you could give a high-level picture of the impact you've observed when it comes to sales and market penetration for these rares.

Mike Gorenstein

executive
#21

Yes. Thank you. No, I'd say the effect has been substantial. It doesn't seem accidental to me that we've incorporated rares into our derivative lineup, with edibles as a major emphasis, and that we've captured the number one market share. In my view, it lends the brand a halo effect. It lets us release a variety of SKUs that are genuinely distinctive and that competitors aren't really providing, and I believe it also gives us the momentum to keep expanding the portfolio. We truly have far more iteration, and we still believe there are plenty of exciting products ahead and that the best is yet to come. So I'd call it a key differentiator. I think the results are visible simply in what we've managed to launch over the last year. So we're quite excited about it, and I think retailers and consumers feel the same way.

Michael Freeman

analyst
#22

That's great. Thanks. Now let's look at the US. We had some disappointing outcomes in Congress at the end of last year, and it appears the timeline for any kind of major reform in the US has been pushed out. I wonder whether you could frame for us your plans regarding entering the US, which is very prominent in your historical strategic plans. I'm wondering if that has changed you to focus more on other geographies given the events of late last year?

Mike Gorenstein

executive
#23

No, that hasn't changed. I think we didn't anticipate any movement whether or not it's a safe path—we didn't expect anything to necessarily shift. I still believe the rescheduling announcement was a catalyst that was underappreciated. But on the whole, we're focused on making sure we've got the right portfolio and borderless product. Because as you'll see in any market, there's certainly an initial wave of excitement with whoever can supply that market first, since there's always that imbalance. But once the market begins to reach a supply-demand equilibrium, what really matters is who has the best branded products. And for us, making sure we continue to have optionality with a strong balance sheet and that great product portfolio—we're ready to move into markets as they open. So when we think about that, that's Israel and the growth we think can continue there. We think Australia, there's certainly some tailwind. Germany of course, and the US. But other markets that start to open up faster, we'll be ready to move.

Operator

operator
#24

Stifel's William Carter has our next question.

Andrew Carter

analyst
#25

Hey, thanks. Andrew here, filling in for William. Just a quick question or two. First, I'd like to ask about gross margin for the quarter. The compression picked up pace. Did any one-time items play a part, and does that gross margin turn meaningfully higher from this point? I'm just trying to get a sense of what actually moves it. I know you mentioned volume deleverage, but pricing has been a help on volume and flower. Any color you could give there would help. Thanks.

James Holm

executive
#26

Okay, thanks Andrew. So the main factors behind the gross profit decline in the ROW segment were an unfavorable price mix shift in cannabis flower and weaker sales in the US business. We also saw an increase in US reserves tied to the strategic repositioning of the portfolio, with more emphasis on adult-use product formats — that's the one-timer you mentioned. And then we had lower fixed cost absorption and packaging changes in the ROW segment. Again, one-time issues, as you said. But those negative effects were partly offset by strong cannabis flower sales in Israel and by growth in cannabis extract sales in Canada, which carries a higher margin profile than other product categories. Israel achieved significant operating leverage and cost structure improvement, going from $13.4 million in revenue in '21 to $30.5 million in revenue in '22 — a 128% increase. And finally, we benefited from lower cannabis biomass costs as we keep leveraging our joint venture with Cronos GrowCo — so we don't anticipate, obviously to the extent you can such things, but don't anticipate any future one-timer there. So hopefully more of a normalization on the gross margin profile.

Mike Gorenstein

executive
#27

Thanks. Just to build on that, another item we touched on somewhat during the prior quarter as we made the shift from Peace Natural over to GrowCo involved several supply chain disruptions that affected us. So in terms of efficiency when fulfilling orders — and you noticed some of this on the top line too — that did have an overall impact on margin. We therefore believe we'll return to normalization now that we've more or less resolved it, with the same warehouse and distribution we had previously and with the ability to optimize the still rate.

Andrew Carter

analyst
#28

All right. The second thing I wanted to ask — since your remarks at the end there did highlight some of the additional checks you ran against your strategy around market share products — but clearly the market looks very different from what we expected 5 years ago. So I suppose my question is: with the cash you have on hand, do you feel any urgency to step out and present a more concrete case? For instance, how do you view the asset landscape across cannabis, in Canada and other places, with many of those assets broken? We saw a few interesting deals last week. Could you offer any perspective on that? Thanks.

Mike Gorenstein

executive
#29

Certainly. I see several assets that look appealing. A few of them have to be carved out from other parts that, in my view, would otherwise erode the value contained in them. We had thought that would move along more quickly. Depending on which market you mean, I'd say we are getting nearer and nearer. The assets come in different kinds. Still, what I want to emphasize is that our continuing focus will be on whatever delivers long-term stickiness from the consumer's standpoint. So supply chain assets aren't really where our attention sits — branded products are. And I believe a few of those exist out there, though I think there is still work to be done and still some movement needed before a number of them become appealing, yet there remains a smaller group of them on which we were unable to act.

Operator

operator
#30

John Zamparo from CIBC has our next question.

John Zamparo

analyst
#31

Appreciate it, and good morning. My question concerns the Peace Natural facility and the choice to stay put there. Mike, you mentioned how this sector's landscape keeps shifting, so I'm wondering what exactly happened, perhaps late in Q3 or early in Q4, that drove the call to keep a portion of that facility operating. It looks as though you're retaining quite a few functions. Was it that costs at third-party providers climbed, or is there some control you wish to hold onto, or something proprietary? I'm simply curious about what changed here.

Mike Gorenstein

executive
#32

Yeah, thank you. There are several factors at play, I'd say. Above all, we needed confidence that our capabilities would let us perform both now and going forward. Along those lines, distribution warehousing matters a great deal. Certain R&D work we were keen to ensure we could keep up. And with some of the proprietary products, our preference is simply to retain manufacturing internally — we identified an advantage in doing so. Yet another major consideration, I'd say, is that in light of how well GrowCo has been performing, reaching profitability so fast with plenty of optimization still ahead, our own move into GrowCo, in a sense, somewhat crowded and constrained GrowCo's room to expand, and likewise somewhat limited the growth I believe we could achieve. So remaining, I think, provides us near-term capacity to execute with improved order fulfillment and stronger margins, while over the longer run allowing both our company and GrowCo to keep seeing growth — and that truly was the decisive element.

John Zamparo

analyst
#33

Alright, that helps a lot—thanks. Now for my follow-up questions about the rare strategy. I'm curious what success would look like from your perspective here. I think I've raised this before, but I'm wondering whether you can give an update on precisely who the buyers are. Is there some repeat-customer component? Is much of it trial driven by novelty? I'd be interested to know if you have any insights into the consumer within your rare's portfolio.

Mike Gorenstein

executive
#34

Yeah, I think repeat business is definitely happening. We’ve got an entire sub-brand focused on rare, and it’s performing well. When we discuss what success looks like, it comes down to being able to offer that incremental set of SKUs without truly cannibalizing your other SKUs, since the customer is after a targeted effect. That matters a great deal. It’s a really crucial element of differentiation and a crucial element of the overall construction portfolio—whether we’re talking CBN, CBG, or CBC, which we’re extremely excited about—and now being able to begin iterating, adding, and combining various cannabinoids. That’s where you’ll see the next level of success we can achieve. But in this market, when you go into many dispensaries, everything looks identical. Having something different, something more targeted, so that when people ask for effects you can offer something with a bit more substance behind it than just <<inaudible>>—that’s really important to knowledgeable consumers.

Operator

operator
#35

We'll now take a question from Cowen's Vivien Azer.

Vivien Azer

analyst
#36

Thank you, and good morning. Mike, I'd like to ask whether you could share some thoughts on the announcement OCS made recently regarding the shift in their margin profile, and how your team is approaching that with respect to your pricing and the competitive landscape as well. Thanks.

Mike Gorenstein

executive
#37

Sure. I think it's still quite soon to determine how the competitive landscape will be affected. Overall, I'd call it a move in the right direction. I think it's genuinely good to see recognition that the industry faces structural challenges and that there are many difficulties for LPS in terms of being sustainable and reaching profitability. I still believe much more remains to be done. But seeing that happen is appreciated. Still, it's quite soon to tell whether this is a situation where price is taken, or whether, if you ultimately see the value from it, we'll probably have a clearer picture of that by next quarter.

Vivien Azer

analyst
#38

All right, that helps. Then for my follow-up: there were quite a few mentions of innovation, and that all makes sense, especially considering the differentiation you're able to deliver through your genetics and the rare cannabinoids. But given your ongoing emphasis on costs, could you explain how you approach inventory management and SKU rationalization, and what kinds of controls you've put in place to oversee that? Thanks.

Mike Gorenstein

executive
#39

Absolutely. One element we've implemented — and in my view it has proven quite beneficial — is the arrangement we have in place with GrowCo, under which we aren't the ones doing the cultivation and then hunting for a way to move whatever product we end up with, regardless of whether it meets our specification. If you're running a grow entirely by yourself, that would be fine. Say the spec we need for a particular strain is 26% to 30%, and it lands at 31% or at 24% — all at once you can't move it, and you're left figuring out what to do, which is the situation when you operate more as a sourcing model. I believe that makes things far more efficient. So there's reduced risk of inventory write-down. And I'd say that's among the most helpful things we've observed, along with having several markets we can push into while GrowCo is able to sell to third parties as well — that really makes sense.

Operator

operator
#40

Tamy Chen with BMO Capital Markets has our next question.

Tamy Chen

analyst
#41

Thank you, and good morning. For my first question, I want to follow up a bit on something another participant raised. Mike, I'm curious whether you could address the Canadian market specifically at this moment. You mentioned the unfavorable price mix trends and noted that the market still carries more weight toward 28 grams. There was also discussion of the OCS announcement as a modest step in the right direction, but how would you characterize the Canadian recreational market at this point? It seems as though the movement toward more aggressive pricing and greater margin pressure from everyone involved simply keeps following that same trend. Is that how you see it? Do you believe anything is on the horizon, or something eventually, that might improve the fundamentals in this market? And is your strategy right now simply to keep investing in things such as the rare cannabinoids as your point of differentiation?

Mike Gorenstein

executive
#42

Absolutely, that's a terrific question. And it isn't only about rare cannabinoids. On this point, I'd use the edible segment as an illustration. Broadly speaking, we managed to land the number one spot in edible. And we aren't accomplishing that by being a value brand in rare, and definitely not by being among those competing in a race to the bottom on price. We pulled that off even as the chewable extract exists, which is genuinely discovering methods to undercut the prices of more conventional edibles. And I believe that simply demonstrates that when your products are differentiated — and really, the further removed you are from flower, the simpler differentiation becomes and the more able you are to capture market. What I believe that implies going forward, and this is the reason we place such emphasis on borderless products, is that you will need to keep doing that within every category. And when I consider the flower category, genetics certainly count, but I believe pre-rolls are truly the space where we can differentiate. And you can see it, yet it resembles tobacco. Pipe tobacco isn't a particularly large category, but you do see cigarettes that separate.

Mike Gorenstein

executive
#43

My view is that pre-rolls offer a great deal of room for standing out. It strikes me as a category much like edible. Some really niche brands, I believe, will manage to set themselves apart. It can hinge heavily on the product. And if that isn't something you can pull off, then I think we edge nearer and nearer to peddling a commodity. And the move we've witnessed toward the 28 gram bag only backs that up.

Tamy Chen

analyst
#44

Understood. All right. I wanted to return to what Andrew asked regarding your cash position. That is quite a substantial sum of cash. So I'd like to put the question to you plainly: what is your thinking there? Beyond financing your existing operations, do you have any plans for it? Thank you.

Mike Gorenstein

executive
#45

Sure, yes. I mean, clearly as rates keep shifting, you're going to begin seeing fairly substantial interest income, I believe. That said, I'd say that's the less compelling portion of what you're after. What I can say is that discipline will remain our approach. And something we aren't pursuing is assets where it's nothing but price-based rivalry and a race to the bottom. Gaining market share isn't meaningful if cash generation isn't there — we think about the whole picture: how do we get to positive cash flow? Adjusted EBITDA isn't on our minds, so those assets are quite specific. What we're examining is how they fit in now and going forward, and in cannabis, having cash is, I'd say, both very uncommon and extremely valuable. So I'd say we're in a highly fortunate spot. We definitely receive a great deal of inbound interest. Plenty of assets are on offer, yet we'll keep being disciplined the way we always have been and ensure whatever we hold is a truly strong fit.

Mike Gorenstein

executive
#46

We’re not going to scale back our position on items with just a one-year lifespan.

Operator

operator
#47

We'll take our next question from Nadine Sarwat at Bernstein.

Nadine Sarwat

analyst
#48

Hello, and thanks for taking the question. I have two for you, please. The first concerns gross margin. You did reference those one-time impacts during the quarter. Can you help us size what those one-time impacts amounted to? Or, to frame it differently, what would gross margin have come in at absent them? And once those items fully fall away, how should we think about a normalized gross margin looking ahead for each of your segments? My second question relates to Israel. That country keeps delivering strong performance for you, which stands out against many of your peers. So could you update us on the underlying trends you are observing in that market and on how you expect things to develop there over this year? Thank you.

James Holm

executive
#49

Sure. Yeah. So regarding the margin, as we mentioned, there were one-time effects from the US portfolio repositioning. We had higher inventory reserves, and then we ran into some fixed cost absorption problems because of the supply chain issues Mike brought up earlier. But we were moving the supply chain around, right, toward our contract manufacturers. And then we had packaging changes in the ROW segment. So I'd say gross margin would have been considerably better absent those items. We do expect things to normalize once those are gone, right. So roughly back to what we would have anticipated for the 2022 year, and that's what we expect in 2023. And obviously we're guiding toward hoped-for improvement there given all the actions we're taking. And I'll pass it to Mike for the Israel question.

Mike Gorenstein

executive
#50

Thanks, James. So once more, the results our Israel team keeps delivering are something we're genuinely pleased about. What I'd say is that our setup differs quite a bit from what I believe the peer we have in Canada has, simply because most others have usually viewed that market as a kind of channel for offloading surplus product, whereas we saw it as a chance to establish a business for the long haul and to build a brand. We've had people on the ground in Israel for quite some time. At this point they've managed to secure distribution across nearly every pharmacy that currently sells cannabis. And right now it's a very appealing industry for both companies and patients. I think another point, when you consider the future and how things develop, is that in January there was an announcement you may see from the government launching a drive for a fresh regulatory change that would open up the market considerably when it comes to patient count and pharmacies. Yet within a week, actually, the health minister who had been charged saw his position become uncertain, and someone else is now in that role. So the situation is fluid. Still, I do believe there's a solid chance we'll see a regulatory change in Israel that expands the market further, though it's early on timing, but it would certainly be helpful.

Operator

operator
#51

Thank you. At this point, I'd like to hand the call over to Mike Gorenstein.

Mike Gorenstein

executive
#52

I appreciate everyone joining us, and I hope the rest of your day goes well.

Operator

operator
#53

We appreciate everyone joining us on today's call. That brings the program to an end. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.